Reena Pharma India Private Limited
About Reena Pharma India Private Limited
Data last updated: 06 January 2026
Reena Pharma India Private Limited is a private limited company based in Navi Mumbai, Maharashtra, India. It specialises in industrial chemicals, a part of the broader chemicals and materials sector. Incorporated on 16 July 2001, the company has been in operation for over 25 years.
Registered with ROC Mumbai under CIN U24231MH2001PTC132736.
Capital: an authorised share capital of ₹20 Lakh and a paid-up capital of ₹19.5 Lakh. It is led by directors including Ila Haresh Mehta and Shivagouda Shidagouda Patil.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No A – 146/6 Ttc Indusrtial Area Midc Kherane Thane Belapur Road, Navi Mumbai, Maharashtra, India – 400705.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.34 Cr, a decline of 55% compared to the previous year.
The company has a workforce of approximately 7 employees as per the latest available data.
As per MCA filings, the company has open charges of ₹88 Lakh and satisfied charges of ₹6.91 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website**************
-
Social Media**************
-
Registered AddressPlot No A – 146/6 Ttc Indusrtial Area Midc Kherane Thane Belapur Road, Navi Mumbai, Maharashtra, India – 400705
-
IndustryChemicals and Materials, Industrial Chemicals
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Reena Pharma India Private Limited
Reena Pharma India Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including manufacture of chemicals and chemical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 20 | Manufacture of chemicals and chemical products | ********* |
Auditor Details of Reena Pharma India Private Limited
Reena Pharma India Private Limited is audited by NEERAV M. SANGHAVI for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| NEERAV M. SANGHAVI | blur-value | blur-value | blur-value |
Board of Directors of Reena Pharma India Private Limited
Reena Pharma India Private Limited is governed by 5 directors who oversee the company's operations and strategic decisions.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ila Haresh Mehta
Also directs:
Unifro Textiles Private Limited
|
Director | 01 Nov 2012 | 13 Years 8 Months | Current |
| Shivagouda Shidagouda Patil | Director | 16 Jul 2001 | 24 Years 11 Months | Current |
|
Haresh Jethalal Mehta
Also directs:
Unifro Textiles Private Limited
|
Director | 01 Nov 2012 | 13 Years 8 Months | Current |
| Shashidhar Shivagouda Patil | Director | 01 Jul 2013 | 13 Years 0 Months | Current |
| Savita Shivgoda Patil | Director | 16 Jul 2001 | 24 Years 11 Months | Current |
Financials of Reena Pharma India Private Limited FY 2025 filings available
Reena Pharma India Private Limited reported revenue of ₹1.34 Cr (down 55% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Reena Pharma India Private Limited
As of FY 2023, Reena Pharma India Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Reena Pharma India Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2024 | Others | ₹51 Lakh | Open |
| 11 Aug 2021 | New India Co-Op Bank Limited | ₹17 Lakh | Open |
| 27 Jun 2018 | New India Co-Op Bank Limited | ₹20 Lakh | Open |
| 07 Apr 2014 | New India Co-Op Bank Limited | ₹1.5 Cr | Satisfied |
| 07 Apr 2014 | New India Co-Op Bank Limited | ₹1.5 Cr | Satisfied |
Total charge records: 13 View all charges
Employees and EPFO Compliance at Reena Pharma India Private Limited
Reena Pharma India Private Limited has a workforce of 7 employees as of Apr 01, 2024.
Employee Count & EPFO Data of Reena Pharma India Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Reena Pharma India Private Limited
GSTIN & GST Filing Data of Reena Pharma India Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Reena Pharma India Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Reena Pharma India Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Reena Pharma India Private Limited
MSME Payment Delays by Reena Pharma India Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Reena Pharma India Private Limited
Subsidiaries & Group Companies of Reena Pharma India Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Reena Pharma India Private Limited with ownership details.
MCA Filings & Documents of Reena Pharma India Private Limited
MCA Filings & Documents of Reena Pharma India Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Reena Pharma India Private Limited
Frequently Asked Questions about Reena Pharma India Private Limited
Reena Pharma India Private Limited is an active private limited company in the chemicals and materials sector based in Navi Mumbai, Maharashtra, India. It was incorporated on 16 July 2001 (25+ years old) and is registered under CIN U24231MH2001PTC132736. The company has 7 employees.
Reena Pharma India Private Limited reported revenue of ₹1.34 Cr for FY 2025 (down 55.00% YoY).
The current directors of Reena Pharma India Private Limited are:
The primary industry of Reena Pharma India Private Limited is chemicals and materials. The company specifically operates in industrial chemicals. The company is currently active in this sector.
Reena Pharma India Private Limited can be reached at the registered office: Plot No A – 1466 Ttc Indusrtial Area Midc Kherane Thane Belapur Road, Navi Mumbai, Maharashtra, India – 400705.
The authorised capital is ₹20 Lakh, and the paid-up capital is ₹19.5 Lakh.